Polaris GroupTPE:6550 -1.87%56 Days Payable is 4.67 as of Dec. 2025, which is 31% below its 10-year median of 6.72. GuruFocus rates TPE:6550 with a GF Score™ of 56/100 and a GF Value™ of NT$55.26 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 702 Biotechnology companies, Polaris Group ranks worse than 99% on this metric.
The historical rank and industry rank for Polaris Group's Days Payable or its related term are showing as below:
TPE:6550'
s Days Payable Range Over the Past 10 Years
Min: 4.43 Med: 6.72 Max: 74.17
Current: 4.43
During the past 12 years, Polaris Group's highest Days Payable was 74.17. The lowest was 4.43. And the median was 6.72.
TPE:6550's Days Payable is ranked worse than 99% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs TPE:6550: 4.43
Polaris Group's Days Payable
increased
from Dec. 2024 (3.00) to Dec. 2025 (4.67).
It may suggest that Polaris Groupdelayed paying its suppliers.
Polaris Group Days Payable Related Terms
Polaris Group Days Payable Historical Data
* Premium members only.
The historical data trend for Polaris Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6550 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Polaris Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polaris Group Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Polaris Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Polaris Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Polaris Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polaris Group (TPE:6550) has a Days Payable of 4.67 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Polaris Group and its competitors. This is 31% below median its historical median of 6.72. Over the past decade, Polaris Group's Days Payable has ranged from 4.43 to 74.17. According to the industry distribution chart, Polaris Group ranks #695 out of 702 companies in the Biotechnology industry, placing it in the top 99%.
Is Polaris Group's Days Payable too high?
Polaris Group's current Days Payable of 4.67 is 31% below median its 10-year median of 6.72. Over the past 10 years, this metric has ranged from a low of 4.43 to a high of 74.17. The Biotechnology industry median Days Payable is 113.56. Polaris Group's value of 4.67 is 95.9% below this industry median. Based on the distribution chart, Polaris Group ranks #695 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Polaris Group has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Polaris Group's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Polaris Group ranks #695 out of 702 companies for Days Payable. This places Polaris Group in the lower half of its industry. The industry median Days Payable is 113.56. Polaris Group's value of 4.67 is 95.9% below this benchmark. Historically, Polaris Group's own Days Payable has ranged from 4.43 to 74.17 over the past decade. While the company's 10-year median is 6.72 vs. the industry median of 113.56, Polaris Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polaris Group's current Days Payable of 4.67 is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Polaris Group and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polaris Group's current Days Payable is 4.67, which is 31% below median its own 10-year median of 6.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaris Group stock overvalued right now?
Based on GuruFocus' analysis, Polaris Group (TPE:6550) is currently considered Possible Value Trap. The stock's GF Value™ is NT$55.26, compared to a current price of NT$13.15 — trading 76.2% below its estimated fair value. The current Days Payable is 4.67, which is 31% below median its 10-year median of 6.72 and 95.9% below the Biotechnology industry median of 113.56. Polaris Group's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Polaris Group (TPE:6550), the current Days Payable is 4.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polaris Group (TPE:6550) Overvalued in 2026?
Based on GuruFocus' analysis, Polaris Group stock appears to be undervalued.
The current stock price of NT$13.15 is trading 76.2% below its estimated GF Value™ of NT$55.26.
GuruFocus considers Polaris Group to be Possible Value Trap.
Key valuation signals for TPE:6550:
Days Payable: 4.67 (31% below median its 10-year median of 6.72)
GF Value™: NT$55.26 vs. price of NT$13.15 (76.2% below fair value)
Industry Position: 95.9% below the Biotechnology median (#695 of 702)
No single metric tells the full story. See the TPE:6550 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.
56GF Score
Get the complete analysis for TPE:6550
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6550 has been successfully added to your 
